AI assistant
KANABO GROUP PLC Remuneration Information 2021
4978_def-14a_2021-12-31_f9624223-10d6-4e50-bace-3fb5aa6af702.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 1890X
Kanabo Group PLC
31 December 2021
Kanabo Group Plc
("Kanabo" or the "Company")
Grant of Options
Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis company that focuses on developing and commercialising cannabis-derived products for medical patients and wellness CBD consumers announces the grant of options over a total of 3,150,000 shares to certain employees, including General Manager, Michal Ben Moshe, pursuant to their terms of employment.
| Name | No. of Options | Vested options as of today | Option Exercise Price | Vesting Period for non-vested options |
| Michal Ben Moshe )PDMR) |
2,025,000 | 506,250 | 16.5p | Options shall vest in 12 equal tranches every three months over a 3-year period. |
| Other employees | 1,125,000 | - | 16.5p | Options shall vest over a 4-year period, with 25% vesting at the end of the first 12-months ("the Initial Vesting") and the remaining 75% vesting in 12 equal tranches every three months following the Initial Vesting. |
For further information, please visit http://www.kanabogroup.com/ or contact the following:
| Kanabo Group Plc | |
| Avihu Tamir, CEO | Via Vox Markets |
| Peterhouse Capital Ltd | |
| Eran Zucker (Financial Adviser) | Tel: +44 (0)20 7469 0930 |
| Lucy Williams / Charles Goodfellow (Corporate Broker) | Tel: +44 (0)20 7469 0930 |
| Vox Markets (Investor Relations) | |
| Kat Perez | [email protected] |
About Kanabo Group Plc
Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers. It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.
The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation in relation to the transaction listed above is set out below.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Michal Ben Moshe | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Manager | |||
| b) | Initial notification /Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Kanabo Group Plc | |||
| b) | LEI | 213800XPJFSNWJIYKN52 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares | |||
| Identification code | GB00BYQCS703 | ||||
| b) | Nature of the transaction | Share Options | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 16.5p | 2,025,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A | ||||
| - Price | N/A | ||||
| e) | Date of the transaction | 24.10.2021 | |||
| f) | Place of the transaction | London Stock Exchange |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHDKDBPCBDKCBN